What is Carmat S.A. (CKMTF) stock price today?

Carmat S.A. (CKMTF) is currently trading at $12.75, down 50.96% today.

What is CKMTF P/E ratio?

Carmat S.A.'s P/E ratio is -0.04. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CKMTF return on equity (ROE)?

Carmat S.A.'s return on equity (ROE) is 106.81%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Carmat S.A.'s market cap?

Carmat S.A. has a market capitalization of $85.19M.

OTC · Medical - Devices

Carmat S.A. (CKMTF) Stock

$12.75 -50.96% OTC: CKMTF Healthcare

Carmat S.A. is dedicated to engineering and producing cutting-edge total artificial hearts.

Valuation

Metric	Value
Price	$12.75
Market Cap	$85.19M
P/E Ratio	-0.04
P/B Ratio	-0.04
P/S Ratio	0.91
EPS (TTM)	$-2.18
52-Week High	$12.75
52-Week Low	$12.75
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	106.81%
ROA	-121.14%
ROCE	-210.64%
Gross Margin	-336.56%
Operating Margin	-702.86%
Net Margin	-734.29%
Debt/Equity	-1.13
Current Ratio	1.70

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$0	$2.0M	$0	$3.0M
Operating Profit	$-42.0M	$-36.0M	$-60.0M	$-52.0M	$-52.0M
Net Profit	$-43.0M	$-37.0M	$-62.0M	$-54.0M	$-54.0M
EPS	$-3.38	$-2.85	$-3.98	$-2.37	$-2.18
Op Margin	-302812.9%	-404572.3%	-2700.4%	-13957.5%	-1875.0%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$65.0M	$60.0M	$69.0M	$85.0M	$53.0M
Total Liabilities	$40.0M	$67.0M	$83.0M	$83.0M	$97.0M
Cash	$56.0M	$36.0M	$39.0M	$51.0M	$8.0M
Borrowings	$16.0M	$39.0M	$52.0M	$55.0M	$58.0M

Latest News

TowneBank Q2 Earnings, Revenue Rise MT Newswires · Jul 23, 2026 Renault says sales stalled in first half AFP · Jul 23, 2026 Should You Buy Amazon and Meta Platforms Stocks Before July 29? Motley Fool · Jul 23, 2026 argenx Q2 Profit, Total Operating Income Rise MT Newswires · Jul 23, 2026 STMicroelectronics Q2 Non-GAAP Earnings, Revenue Rise MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-40.0M	$-43.0M	$-60.0M	$-54.0M	$-53.0M
Investing Cash Flow	$-1.0M	$-5.0M	$-4.0M	$-4.0M	$-10.0M
Financing Cash Flow	$71.0M	$26.0M	$65.0M	$69.0M	$15.0M
Net Cash Flow	$30.0M	$-20.0M	$3.0M	$12.0M	$-43.0M
Free Cash Flow	$-41.0M	$-45.0M	$-62.0M	$-56.0M	$-59.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.19
FCF Yield	-704.64%
Quick Ratio	0.66
Interest Coverage	-15.37
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADOIF	$8.87	+0.00%	-2.46	$103.66M	0.00%
AMEUFAnteris Technologies Ltd	$5.70	-35.81%	-3.37	$120.50M	0.00%
ETXPFE-therapeutics Plc	$0.13	+0.00%	-4.71	$75.96M	0.00%
JMDMFJapan Medical Dynamic Marketing, Inc.	$5.00	+0.00%	-76.22	$131.77M	2.00%
KIARFKiaro Holdings Corp.	$0.00	—	0.00	$442	0.00%

About Carmat S.A.

Carmat S.A. is dedicated to engineering and producing cutting-edge total artificial hearts. These innovative devices are developed to aid patients afflicted with severe, end-stage biventricular heart failure, serving markets in France and across the globe. The company was established in 2008 and operates from its primary base in Vélizy-Villacoublay, France.

Carmat S.A. is headquartered in FR.

Carmat S.A. (CKMTF) stock trades at $12.75 with a market capitalization of $85.19M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.04, reflecting a net loss over the last twelve months, a negative price-to-book of -0.04, reflecting negative shareholders' equity, price-to-sales of 0.91. Over the past 52 weeks the stock has ranged between $12.75 and $12.75, and currently trades at or near its 52-week high.

On profitability, Carmat S.A. generates a return on equity (ROE) of 106.81% (not meaningful, as shareholders' equity is negative), return on capital employed of -210.64%, an operating margin of -702.86%, a net profit margin of -734.29%.

Official website: www.carmatsa.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.33 -0.55% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.58 -0.16%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.